Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco.

El Fatemi H, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, Mesbahi O, Amarti A.

Diagn Pathol. 2012 Dec 7;7:170. doi: 10.1186/1746-1596-7-170. Retraction in: Diagn Pathol. 2013;8:127.

2.

Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.

Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA.

BMC Cancer. 2010 May 21;10:223. doi: 10.1186/1471-2407-10-223.

3.

Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study.

Bennis S, Abbass F, Akasbi Y, Znati K, Joutei KA, El Mesbahi O, Amarti A.

BMC Res Notes. 2012 Aug 13;5:436. doi: 10.1186/1756-0500-5-436.

4.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
5.

Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.

Cherbal F, Gaceb H, Mehemmai C, Saiah I, Bakour R, Rouis AO, Boualga K, Benbrahim W, Mahfouf H.

Breast Dis. 2015;35(2):95-102. doi: 10.3233/BD-150398.

PMID:
25736840
6.

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.

JAMA. 2006 Jun 7;295(21):2492-502.

PMID:
16757721
7.

Identification of different subtypes of breast cancer using tissue microarray.

Munirah MA, Siti-Aishah MA, Reena MZ, Sharifah NA, Rohaizak M, Norlia A, Rafie MK, Asmiati A, Hisham A, Fuad I, Shahrun NS, Das S.

Rom J Morphol Embryol. 2011;52(2):669-77.

8.

Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.

Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE.

BMC Womens Health. 2014 Aug 29;14:102. doi: 10.1186/1472-6874-14-102.

9.

Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma.

Delgallo WD, Rodrigues JR, Bueno SP, Viero RM, Soares CT.

Cytopathology. 2010 Aug;21(4):259-66. doi: 10.1111/j.1365-2303.2009.00713.x. Epub 2009 Oct 15.

PMID:
19843143
10.

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M.

BMC Med Genomics. 2012 Oct 4;5:44. doi: 10.1186/1755-8794-5-44.

11.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
12.

Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.

O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC.

Clin Cancer Res. 2010 Dec 15;16(24):6100-10. doi: 10.1158/1078-0432.CCR-10-1533.

13.

[Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].

Ruano R, Ramos M, García-Talavera JR, Ramos T, Rosero AS, González-Orus JM, Sancho M.

Rev Esp Med Nucl Imagen Mol. 2014 Nov-Dec;33(6):340-5. doi: 10.1016/j.remn.2014.04.003. Epub 2014 May 21. Spanish.

14.

Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer.

Howland NK, Driver TD, Sedrak MP, Wen X, Dong W, Hatch S, Eltorky MA, Chao C.

J Surg Res. 2013 Dec;185(2):697-703. doi: 10.1016/j.jss.2013.06.048. Epub 2013 Jul 11.

15.

Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.

Bhargava R, Beriwal S, Striebel JM, Dabbs DJ.

Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):113-8. doi: 10.1097/PAI.0b013e3181b94ff1.

PMID:
19801938
16.

Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.

Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO.

BMC Cancer. 2011 Jul 12;11:292. doi: 10.1186/1471-2407-11-292.

17.

Molecular subtyping of male breast cancer by immunohistochemistry.

Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ.

Mod Pathol. 2012 Mar;25(3):398-404. doi: 10.1038/modpathol.2011.174. Epub 2011 Nov 4.

18.

Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer.

Tsang JY, Wong KH, Lai MW, Lacambra MD, Ko CW, Chan SK, Lam CC, Yu AM, Tan PH, Tse GM.

J Clin Pathol. 2013 Apr;66(4):291-6. doi: 10.1136/jclinpath-2012-201027. Epub 2012 Dec 25.

PMID:
23268325
19.

Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.

Feeley LP, Mulligan AM, Pinnaduwage D, Bull SB, Andrulis IL.

Mod Pathol. 2014 Apr;27(4):554-61. doi: 10.1038/modpathol.2013.153. Epub 2013 Sep 20.

20.

Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.

Marotti JD, Collins LC, Hu R, Tamimi RM.

Mod Pathol. 2010 Feb;23(2):197-204. doi: 10.1038/modpathol.2009.158. Epub 2009 Nov 6.

Supplemental Content

Support Center